Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons <i>In vitro</i> and <i>In vivo</i>

15 Jan 2007

Abstract excerpt

PURPOSE: Chk1 kinase is a critical regulator of both S and G(2)-M phase cell cycle checkpoints in response to DNA damage. This study aimed to evaluate the biochemical, cellular, and antitumor effects of a novel Chk1 inhibitor, CHIR124. EXPERIMENTAL DESIGN: CHIR-124 was evaluated for its ability to abrogate cell cycle checkpoints, to potentiate cytotoxicity, and to inhibit Chk1-mediated signaling induced by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Microbial Natural Products and Biosynthesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17255282
DOI: 10.1158/1078-0432.ccr-06-1424

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons <i>In vitro</i> and <i>In vivo</i>PMID 17255282Read ↗

Chk1 Inhibitors for Novel Cancer TreatmentSemantic proximity Read ↗

Novel Checkpoint 1 InhibitorsSemantic proximity Read ↗

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1Semantic proximity Read ↗

Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosisSemantic proximity Read ↗

Radioprotection by hymenialdisine-derived checkpoint kinase 2 inhibitors.Semantic proximity Read ↗

Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.Semantic proximity Read ↗

Unleashing Chk1 in cancer therapySemantic proximity Read ↗

Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancerSemantic proximity Read ↗

A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastropheSemantic proximity Read ↗

A novel camptothecin derivative, ZBH-01, exhibits superior antitumor efficacy than irinotecan by regulating the cell cycleSemantic proximity Read ↗

Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti‐cancer therapy?Semantic proximity Read ↗

Targeting Topoisomerase I in the Era of Precision MedicineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.